Compounds > vadimezan
Page last updated: 2024-09-03

vadimezan and Experimental Neoplasms

vadimezan has been researched along with Experimental Neoplasms in 16 studies

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (18.75)18.2507
2000's8 (50.00)29.6817
2010's5 (31.25)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bussink, J; Hectors, SJ; Hoeben, FJ; Jacobs, I; Janssen, HM; Keizer, HM; Lok, J; Nicolay, K; Peters, J; Schabel, MC; Strijkers, GJ1
Chen, D; Dong, X; Huang, W; Huang, X; Liang, P; Ou, C; Shao, J; Wang, Y; Zhang, Q1
Banda, T; Corrales, L; Dubensky, TW; Gajewski, TF; Glickman, LH; Kanne, DB; Katibah, GE; Lemmens, E; Leong, JJ; McWhirter, SM; Metchette, K; Sivick, KE; Woo, SR1
Hung, CF; Monie, A; Pang, X; Peng, S; Wu, TC1
Kim, S; Mitchison, TJ; Peshkin, L1
Bellnier, DA; Camacho, SH; Cheney, RT; Gollnick, SO; Greco, WR1
Baguley, BC; Ching, LM; Kestell, P; Zhao, L1
Baguley, BC; Ching, LM; Zwain, S1
Chaplin, DJ; Horsman, MR; Siemann, DW1
Baguley, BC; Ching, LM; Kelland, LR; Kestell, P; Zhao, L1
Bellnier, DA; Camacho, SH; Cheney, RT; Mazurchuk, R; Oseroff, AR; Seshadri, M; Spernyak, JA1
Begent, RH; Boden, JA; Boden, R; Boxer, GM; Flynn, AA; Keep, PA; Pedley, RB1
Happerfield, DW; Knowles, RG; Miles, DW; Moilanen, E; Moncada, S; Thomsen, LL1
Cowan, DS; Li, AE; Siim, BG; Wilson, WR1
Laux, WT; Palmer, BN; Rutland, MD; Siim, BG; Wilson, WR1
Horsman, MR; Murata, R; Overgaard, J; Siemann, DW1

Reviews

1 review(s) available for vadimezan and Experimental Neoplasms

ArticleYear
Vascular-targeting therapies for treatment of malignant disease.
    Cancer, 2004, Jun-15, Volume: 100, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Combined Modality Therapy; Endothelium, Vascular; Neoplasms, Experimental; Organophosphorus Compounds; Stilbenes; Xanthones

2004

Other Studies

15 other study(ies) available for vadimezan and Experimental Neoplasms

ArticleYear
Improved Evaluation of Antivascular Cancer Therapy Using Constrained Tracer-Kinetic Modeling for Multiagent Dynamic Contrast-Enhanced MRI.
    Cancer research, 2018, 03-15, Volume: 78, Issue:6

    Topics: Animals; Capillary Permeability; Contrast Media; Dendrimers; Heterocyclic Compounds; Image Processing, Computer-Assisted; Kinetics; Magnetic Resonance Imaging; Mice, Inbred BALB C; Neoplasms, Experimental; Organometallic Compounds; Placebos; Xanthones

2018
Tumor-Microenvironment-Responsive Nanoconjugate for Synergistic Antivascular Activity and Phototherapy.
    ACS nano, 2018, 11-27, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Agents; Antiviral Agents; Cell Proliferation; Endothelial Cells; HeLa Cells; Humans; Lysosomes; Mice; Nanoconjugates; Neoplasms, Experimental; Optical Imaging; Phototherapy; Tumor Cells, Cultured; Tumor Microenvironment; Vascular Endothelial Growth Factors; Xanthones

2018
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
    Cell reports, 2015, May-19, Volume: 11, Issue:7

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Gene Knockout Techniques; Humans; Macrophages; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms, Experimental; Nucleotides, Cyclic; Polymerase Chain Reaction; Transfection; Tumor Microenvironment; Xanthones

2015
Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines.
    Journal of biomedical science, 2011, Mar-08, Volume: 18

    Topics: Animals; Antineoplastic Agents; Cancer Vaccines; CD8-Positive T-Lymphocytes; Human papillomavirus 16; Humans; Mice; Mice, Inbred C57BL; Models, Animal; Neoplasms, Experimental; Papillomavirus Vaccines; Vaccines, DNA; Xanthones

2011
Vascular disrupting agent drug classes differ in effects on the cytoskeleton.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Capillary Permeability; Cell Line; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Mice; Microtubules; Neoplasms, Experimental; Neovascularization, Pathologic; Stilbenes; Xanthones

2012
Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Cancer research, 2003, Nov-15, Volume: 63, Issue:22

    Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Dihematoporphyrin Ether; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Fibrosarcoma; Mice; Mice, Inbred C3H; Necrosis; Neoplasms, Experimental; Photochemotherapy; Tumor Necrosis Factor-alpha; Xanthones

2003
Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-15, Volume: 9, Issue:17

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Clinical Trials as Topic; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; Time Factors; Xanthones

2003
Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.
    British journal of cancer, 2004, Feb-23, Volume: 90, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Colonic Neoplasms; Endothelial Cells; In Situ Nick-End Labeling; Mice; Mice, Knockout; Neoplasms, Experimental; Regional Blood Flow; Tumor Necrosis Factor-alpha; Xanthones

2004
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
    International journal of cancer, 2005, Aug-20, Volume: 116, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Capillary Permeability; Colonic Neoplasms; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms, Experimental; Neovascularization, Pathologic; Receptors, Tumor Necrosis Factor, Type I; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xanthones

2005
Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-01, Volume: 11, Issue:11

    Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Capillary Permeability; Chlorophyll; Combined Modality Therapy; Dose-Response Relationship, Drug; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Photochemotherapy; Platelet Endothelial Cell Adhesion Molecule-1; Treatment Outcome; Xanthones

2005
Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents.
    Cancer research, 1996, Jul-15, Volume: 56, Issue:14

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality Therapy; Flavonoids; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Radioimmunotherapy; Regional Blood Flow; Serotonin; Tissue Distribution; Transplantation, Heterologous; Xanthenes; Xanthones

1996
Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.
    British journal of cancer, 1998, Volume: 77, Issue:3

    Topics: Animals; Antineoplastic Agents; Enzyme Induction; Immunohistochemistry; Mice; Neoplasms, Experimental; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitrites; Ornithine; Xanthenes; Xanthones

1998
Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
    International journal of radiation oncology, biology, physics, 1998, Nov-01, Volume: 42, Issue:4

    Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Mice; Mice, Inbred C3H; Neoplasm, Residual; Neoplasms, Experimental; Xanthenes; Xanthones

1998
Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic
    Cancer research, 2000, Aug-15, Volume: 60, Issue:16

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Fibrosarcoma; Humans; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Organotechnetium Compounds; Oximes; Radionuclide Imaging; Radiopharmaceuticals; Stilbenes; Xanthenes; Xanthones

2000
Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
    Radiation research, 2001, Volume: 156, Issue:5 Pt 1

    Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Sarcoma, Experimental; Xanthenes; Xanthones

2001